Effect of tocilizumab in adults hospitalized with COVID-19 with moderate or severe pneumonia
What The Study Did: This randomized clinical trial assessed whether tocilizumab improves outcomes of patients hospitalized with moderate-to-severe COVID-19 pneumonia compared to usual care.
Authors: Olivier Hermine, M.D., Ph.D., of the Université de Paris, is the corresponding author.
To access the embargoed study: Visit our For The Media website at this link https:/
Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Media advisory: The full study and editorial are linked to this news release.
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https:/
JAMA Network Media Relations